ACKNOWLEDGMENTS We thank all the patients and their families who participated in the study. We thank Drs. M. Malloy, S. Chhangawala, and M. DeMario for their comments,suggestions, and assistance. We thank A. Lamb, J. Tepper, and M. Molesfor clinical operations support, and T. Kohler for assistance in the revision pro- cess. We thank all BioNTech US (formerly Neon Therapeutics, Inc.) employees for their dedication that enabled this study. We thank John Welle of AcumenMedical Communications for graphic design support. We dedicate this publi-cation to our beloved friend, colleague, and a brilliant scientist Y. Sonia Ting(1984–2019), who brightened our days with her smile and was a beacon ofinnovation. This study was funded by Neon Therapeutics/BioNTech US. AUTHOR CONTRIBUTIONS Conceptualization, Formal Analysis, Investigation, Visualization, and Writing – Original Draft, A.P.; Conceptualization, Methodology, Investigation, Visualiza-tion, and Writing – Original Draft, J.S.; Investigation, Methodology, Visualiza-tion and Writing – Review and Editing, M.E.B.; Investigation and Methodology,R.B.; Investigation, Methodology, and Visualization, K.N.B.; Data Curation,A.W.; Investigation, R.G.W. and J.P.; Clinical Investigators on the Study,P.A.O. and S.H.-L.; Biostatistical Analysis and Data Curation, Z.S.K.; Supervi-sion, Funding Acquisition, and Writing – Review and Editing, R.B.G.; Supervi-sion, Conceptualization, and Writing – Review and Editing, M.S.R.; andSupervision, Conceptualization, and Writing – Review and Editing, L.S. DECLARATION OF INTERESTS A.P., J.S., M.E.B., R.B., K.N.B., A.W., R.G.W., J.P., Z.S.K., M.S.R., and L.S. are/were all employees and/or equity holders at BioNTech US (formerlyNeon Therapeutics, Inc.). P.A.O.: research funding paid to the institution:BMS, Merck, AstraZeneca, Celldex, CytomX, Glaxo Smith Kline, ARMO Bio-sciences; Neon Therapeutics, Consultant: Array, BMS, Merck, Genentech,Pﬁzer, Novartis, Neon Therapeutics, CytomX, Celldex. S.H.-L.: consultant toAmgen, BMS, Genmab, Xencor; Research support from BMS, Merck and Vac-cinex. R.B.G.: Board of Directors, Alkermes plc and Inﬁnity Pharmaceuticalsand Scientiﬁc Advisory Board, Leap Therapeutics; stockholder and employeeof BioNTech US (formerly Neon Therapeutics, Inc.). Received: April 23, 2020 Revised: September 2, 2020 Accepted: October 22, 2020Published: November 17, 2020 REFERENCES 1.Coley, W.B.